Facebook
Twitter
LinkedIn
Forward
(CME Webcast) Improving Outcomes in Patients With Geographic Atrophy: Cases in Clinical Practice - Part 2
Activity Description and Purpose
In part 2 of the webcast series on geographic atrophy, Lejla Vajzovic, MD, and Arshad Khanani, MD, will do a deep dive into current treatment options to optimize patient outcomes. Learners will be enabled to develop treatment plans for patients with geographic atrophy through a review of clinical study data, case scenarios, and real-world cases. This comprehensive session will empower learners to confidently assess and manage geographic atrophy in their practice.
Target Audience
This educational activity is intended for retina specialists and other ophthalmologists.
Learning Objectives
After completing this activity, participants will be better able to:
- Review clinical data for complement inhibitors used in the treatment of geographic atrophy
- Develop appropriate treatment plans for patients with geographic atrophy
Faculty
 | Arshad M. Khanani, MD, MA, FASRS Managing Partner Director of Clinical Research Director of Fellowship Sierra Eye Associates Clinical Professor University of Nevada, Reno School of Medicine Reno, Nevada |
 | Lejla Vajzovic, MD |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Arshad M. Khanani, MD, MA, is a consultant for AbbVie Inc, Adverum, Alcon, Amgen Inc, Annexin Pharmaceuticals, Annexon Inc, Apellis Pharmaceuticals, Astellas Pharma Inc, Aviceda Therapeutics, Beacon Therapeutics, Clearside Biomedical, Inc, Complement Therapeutics GmbH, Exegenesis Bio, EyePoint Pharmaceuticals, F. Hoffmann-La Roche Ltd, 4DMT, Frontera Therapeutics, Inc, Genentech, Inc, Gyroscope, i-Lumen Scientific, Iveric Bio, Inc, Janssen Pharmaceuticals, Inc, Kodiak Sciences Inc, Kriya Therapeutics, Nanoscope Therapeutics, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Oculis, Ocuphire Pharma, OcuTerra Therapeutics, Olive Biotherapeutics, Opthea, Oxular Limited, Oxurion NV, Perfuse Therapeutics, Ray Therapeutics, Recens Medical, Inc, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, ReVive Biotechnology, RevOpsis, Sanofi, Stealth BioTherapeutics Inc, Thea Pharma Inc, Unity Biotechnology, Vanotech, and Vial; and is a contracted researcher for Adverum, Alexion Pharmaceuticals, Inc, Annexon Inc, Apellis Pharmaceuticals, Astellas Pharma Inc, Aviceda Therapeutics, Exegenesis Bio, EyePoint Pharmaceuticals, F. Hoffmann-La Roche Ltd, 4DMT, Genentech, Inc, Gyroscope, Iveric Bio, Inc, Janssen Pharmaceuticals, Inc, Kodiak Sciences Inc, Neurotech Pharmaceuticals, Ocular Therapeutix, Inc, Oculis, OcuTerra Therapeutics, Opthea, Oxular Limited, Oxurion NV, Regenxbio Inc, Unity Biotechnology, and Vanotech.
Lejla Vajzovic, MD, is a consultant for AbbVie Inc, Alcon, Alimera Sciences, Apellis Pharmaceuticals, Astellas Pharma Inc, Bausch & Lomb Incorporated, Beaver-Visitec International, Clearside Biomedical, Inc, Coherus Biosciences, D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., F. Hoffman-La Roche Ltd, Genentech, Inc, Guidepoint, Gyroscope, Iveric Bio, Inc, Janssen Pharmaceuticals, Inc, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, Ocugen, Inc, OCULUS, Inc, OcuTerra Therapeutics, Outlook Therapeutics, Inc, and Regenxbio Inc; is an advisory board member of Astellas Pharma Inc, Clearside Biomedical, Inc, Iveric Bio, Inc, Ocugen, Inc, and Regenxbio Inc; and is a contracted researcher for AGTC, Alcon, Aldeyra Therapeutics, Apellis Pharmaceuticals, F. Hoffmann-La Roche Ltd, Genentech, Inc, Gyroscope, Heidelberg Engineering GmbH, Janssen Pharmaceuticals, Inc, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, and Regenxbio Inc.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Medical Writer: Robert M. Geist IV, MD, is a consultant for Ascendis Pharma Group; and formerly a paid employee of Fresenius Medical Care.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Astellas Pharma Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Astellas Pharma Inc.
This CME activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 318.2BW
Available Credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation